Nicholas, J. A., Racke, M. K., Imitola, J., & Boster, A. L. (2014). First-line natalizumab in multiple sclerosis: Rationale, patient selection, benefits and risks. SAGE Publications.
Chicago-stil citatNicholas, Jacqueline Ann, Michael Karl Racke, Jamie Imitola, och Aaron Lee Boster. First-line Natalizumab in Multiple Sclerosis: Rationale, Patient Selection, Benefits and Risks. SAGE Publications, 2014.
MLA-referensNicholas, Jacqueline Ann, Michael Karl Racke, Jamie Imitola, och Aaron Lee Boster. First-line Natalizumab in Multiple Sclerosis: Rationale, Patient Selection, Benefits and Risks. SAGE Publications, 2014.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.